Novartis: 'real world' data shows psoriasis drug efficacy
(CercleFinance.com) - Real-world data has confirmed the efficacy of Novartis' Cosentyx in daily life for patients suffering from psoriasis, the Swiss drugmaker said on Thursday.
New data from several real-world sources in moderate-to-severe plaque psoriasis confirmed that Cosentyx led to a pronounced improvement in the quality of patients' lives, it said.
More specifically, 59% of patients had no or little impact of their skin disease on their quality of life after 24 weeks of treatment, Novartis said.
Additional real-world data showed that 87% of bio-naive psoriasis patients remain on Cosentyx after 12 months of treatment, further supporting the use of Cosentyx in real-world settings.
All this data was first presented at the European Academy of Dermatology and Venereology (EADV) Congress in Paris.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
New data from several real-world sources in moderate-to-severe plaque psoriasis confirmed that Cosentyx led to a pronounced improvement in the quality of patients' lives, it said.
More specifically, 59% of patients had no or little impact of their skin disease on their quality of life after 24 weeks of treatment, Novartis said.
Additional real-world data showed that 87% of bio-naive psoriasis patients remain on Cosentyx after 12 months of treatment, further supporting the use of Cosentyx in real-world settings.
All this data was first presented at the European Academy of Dermatology and Venereology (EADV) Congress in Paris.
Copyright (c) 2018 CercleFinance.com. All rights reserved.